查看购物车
  • Traditional Chinese
  • English
亚太地区疫苗佐剂市场预测至 2030 年 - 区域分析 - 按佐剂类别（矿物盐佐剂、乳液佐剂、脂质体佐剂等）和类型（人用疫苗佐剂和兽用疫苗佐剂）划分
市场调查报告书
商品编码
1666307

亚太地区疫苗佐剂市场预测至 2030 年 - 区域分析 - 按佐剂类别（矿物盐佐剂、乳液佐剂、脂质体佐剂等）和类型（人用疫苗佐剂和兽用疫苗佐剂）划分

Asia Pacific Vaccine Adjuvants Market Forecast to 2030 - Regional Analysis - by Adjuvant Class (Mineral Salt Adjuvant, Emulsion Adjuvant, Liposome Adjuvant, and Others) and Type (Human Vaccine Adjuvant and Veterinary Vaccine Adjuvant)
出版日期: | 出版商: The Insight Partners | 英文 88 Pages | 订单完成后即时交付

价格

2022年亚太地区疫苗佐剂市值为5.1807亿美元，预计2030年将达到15.4643亿美元；预计 2022 年至 2030 年的复合年增长率为 14.6%。

生物技术和免疫学的进步推动亚太疫苗佐剂市场的发展

由于对增强疫苗效力的需求不断增长以及疫苗应用范围扩大到传统传染病之外，疫苗佐剂市场带来了重大机会。随着新病原体的出现和现有病原体的进化，对能够增强免疫反应并提供更广泛保护的佐剂的需求日益增加。生物技术和免疫学的进步推动了佐剂配方的创新，为预防和治疗疫苗提供了新的解决方案。此外，全球疫苗接种计划的兴起和疫苗研究资金的增加也推动了市场成长。专注于开发安全性更高、效力更高的佐剂的公司有能力利用这个不断扩大的市场。与研究机构和生物技术公司的策略伙伴关係和合作可以进一步增加这个充满活力的领域的机会，使其成为一个有希望的投资和发展领域。

亚太地区疫苗佐剂市场概况

亚太疫苗佐剂市场细分为中国、日本、印度、澳洲、韩国和亚太其他地区。中国公司合作生产佐剂疫苗等策略性措施推动了市场的发展。例如，2020 年 4 月，Dynavax Technologies Corporation 宣布与中国生物製药公司 Sinovac 合作开发 CpG 1018 佐剂。 CpG 1018 是美国食品药物管理局 (FDA) 批准的成人乙肝疫苗 HEPLISAV-B [佐剂型乙肝疫苗 (重组)] 中使用的佐剂，可增强疫苗免疫反应。因此，中国製造商在采购佐剂疫苗方面的合作与伙伴关係等策略发展是推动市场积极成长的独立因素。

亚太地区疫苗佐剂市场收入及 2030 年预测（百万美元）

亚太地区疫苗佐剂市场区隔

亚太地区疫苗佐剂市场分为佐剂类别、类型和国家。

依佐剂类别，亚太疫苗佐剂市场分为矿物盐佐剂、乳液佐剂、脂质体佐剂等。 2022 年，矿物盐佐剂部分占据亚太地区疫苗佐剂市场的最大份额。

根据类型，亚太地区疫苗佐剂市场分为人用疫苗佐剂和兽用疫苗佐剂。 2022 年，人类疫苗佐剂部分在亚太疫苗佐剂市场中占有较大的份额。

依国家划分，亚太疫苗佐剂市场分为中国、日本、印度、澳洲、韩国和亚太其他地区。 2022 年中国占据亚太疫苗佐剂市场的主导份额。

Croda International Plc； CSL有限公司；葛兰素史克公司；夏威夷生物技术公司； InvivoGen SAS； Novavax Inc； Phibro 动物健康公司；和 SPI Pharma Inc 是亚太地区疫苗佐剂市场的一些领先公司。

目录

第 1 章：简介

第 2 章：执行摘要

  • 关键见解

第三章：研究方法

  • 覆盖范围
  • 二次研究
  • 初步研究

第 4 章：亚太地区疫苗佐剂市场 - 主要市场动态

  • 亚太地区疫苗佐剂市场 - 主要市场动态
  • 市场驱动因素
    • 传染病爆发和疫情数量不断增加
    • 兽用疫苗佐剂的核准
  • 市场限制
    • 产品召回和不良影响
  • 市场机会
    • 生物技术和免疫学的进展
  • 未来趋势
    • 技术进步
  • 驱动因素和限制因素的影响：

第 5 章：疫苗佐剂市场 - 亚太市场分析

  • 亚太地区疫苗佐剂市场 - 收入及 2030 年预测
  • 亚太地区疫苗佐剂市场预测与分析

第 6 章：亚太地区疫苗佐剂市场分析 - 按佐剂类别

  • 概述
  • 矿物盐佐剂
  • 乳化助剂
  • 脂质体佐剂
  • 其他的

第 7 章：亚太地区疫苗佐剂市场分析 - 按类型

  • 人类疫苗佐剂
  • 兽用疫苗佐剂

第 8 章：亚太地区疫苗佐剂市场 - 国家分析

  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
    • 亚太地区其他地区

第九章：产业格局

  • 概述
  • 疫苗佐剂市场的成长策略
  • 有机发展
    • 概述
  • 无机发展
    • 概述

第十章：公司简介

  • SPI Pharma Inc
  • GSK Plc
  • CSL Ltd
  • Hawaii Biotech Inc
  • InvivoGen SAS
  • Croda International Plc
  • Novavax Inc
  • Phibro Animal Health Corp

第 11 章：附录

Product Code: BMIRE00031082

The Asia Pacific vaccine adjuvants market was valued at US$ 518.07 million in 2022 and is expected to reach US$ 1,546.43 million by 2030; it is estimated to register a CAGR of 14.6% from 2022 to 2030 .

Advancements in Biotechnology and Immunology Boost Asia Pacific Vaccine Adjuvants Market

The vaccine adjuvants market presents significant opportunities due to the growing demand for enhanced vaccine efficacy and the expansion of vaccine applications beyond traditional infectious diseases. As new pathogens emerge and existing ones evolve, there is an increasing need for adjuvants that can boost immune responses and provide broader protection. Advancements in biotechnology and immunology are driving innovation in adjuvant formulations, offering novel solutions for both preventive and therapeutic vaccines. Additionally, the rise in global vaccination programs and increased funding for vaccine research are fueling market growth. Companies focusing on developing adjuvants with improved safety profiles and higher effectiveness are well-positioned to capitalize on this expanding market. Strategic partnerships and collaborations with research institutions and biotechnology firms can further enhance opportunities in this dynamic field, making it a promising area for investment and development.

Asia Pacific Vaccine Adjuvants Market Overview

The Asia Pacific vaccine adjuvant market has been segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. Strategic initiatives, such as collaborations between Chinese companies to produce adjuvant vaccines, drive the market. For instance, in April 2020, Dynavax Technologies Corporation announced a collaboration with Chinese biopharmaceutical company Sinovac to develop CpG 1018 adjuvant. CpG 1018 is the adjuvant used in HEPLISAV-B [Hepatitis B Vaccine (Recombinant), Adjuvanted], an adult hepatitis B vaccine approved by the US Food and Drug Administration (FDA) to increase vaccine immune response. Therefore, strategic developments such as collaboration and partnerships by the Chinese manufacturers for procuring adjuvanted vaccines is a standalone factor responsible for positive market growth.

Asia Pacific Vaccine Adjuvants Market Revenue and Forecast to 2030 (US$ Million)

Asia Pacific Vaccine Adjuvants Market Segmentation

The Asia Pacific vaccine adjuvants market is categorized into adjuvant class, type, and country.

Based on adjuvant class, the Asia Pacific vaccine adjuvants market is segmented into mineral salt adjuvant, emulsion adjuvant, liposome adjuvant, and others. The mineral salt adjuvant segment held the largest share of the Asia Pacific vaccine adjuvants market share in 2022.

By type, the Asia Pacific vaccine adjuvants market is bifurcated into human vaccine adjuvant and veterinary vaccine adjuvant. The human vaccine adjuvant segment held a larger share of Asia Pacific vaccine adjuvants market in 2022.

By country, the Asia Pacific vaccine adjuvants market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific vaccine adjuvants market share in 2022.

Croda International Plc; CSL Ltd; GSK Plc; Hawaii Biotech Inc; InvivoGen SAS; Novavax Inc; Phibro Animal Health Corp; and SPI Pharma Inc are some of the leading companies operating in the Asia Pacific vaccine adjuvants market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. Asia Pacific Vaccine Adjuvants Market - Key Market Dynamics

  • 4.1 Asia Pacific Vaccine Adjuvants Market - Key Market Dynamics
  • 4.2 Market Drivers
    • 4.2.1 Rising Number of Infectious Disease Outbreaks and Pandemic
    • 4.2.2 Approvals of Veterinary Vaccine Adjuvants
  • 4.3 Market Restraints
    • 4.3.1 Product Recalls and Adverse Effects
  • 4.4 Market Opportunity
    • 4.4.1 Advancements in Biotechnology and Immunology
  • 4.5 Future Trends
    • 4.5.1 Technological Advancements
  • 4.6 Impact of Drivers and Restraints:

5. Vaccine Adjuvants Market -Asia Pacific Market Analysis

  • 5.1 Asia Pacific Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • 5.2 Asia Pacific Vaccine Adjuvants Market Forecast and Analysis

6. Asia Pacific Vaccine Adjuvants Market Analysis - by Adjuvant Class

  • 6.1 Overview
  • 6.2 Mineral Salt Adjuvant
    • 6.2.1 Overview
    • 6.2.2 Mineral Salt Adjuvant: Asia Pacific Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.3 Emulsion Adjuvant
    • 6.3.1 Overview
    • 6.3.2 Emulsion Adjuvant: Asia Pacific Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.4 Liposome Adjuvant
    • 6.4.1 Overview
    • 6.4.2 Liposome Adjuvant: Asia Pacific Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.5 Others
    • 6.5.1 Overview
    • 6.5.2 Others: Asia Pacific Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

7. Asia Pacific Vaccine Adjuvants Market Analysis - by Type

  • 7.1 Human Vaccine Adjuvant
    • 7.1.1 Overview
    • 7.1.2 Human Vaccine Adjuvant: Asia Pacific Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.2 Veterinary Vaccine Adjuvant
    • 7.2.1 Overview
    • 7.2.2 Veterinary Vaccine Adjuvant: Asia Pacific Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

8. Asia Pacific Vaccine Adjuvants Market -Country Analysis

  • 8.1 Asia Pacific
    • 8.1.1 Asia Pacific: Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Country
      • 8.1.1.1 China: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 8.1.1.1.1 Overview
        • 8.1.1.1.2 China: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 8.1.1.1.3 China: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 8.1.1.1.4 China: Vaccine Adjuvants Market Breakdown, by Type
      • 8.1.1.2 Japan: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 8.1.1.2.1 Overview
        • 8.1.1.2.2 Japan: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 8.1.1.2.3 Japan: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 8.1.1.2.4 Japan: Vaccine Adjuvants Market Breakdown, by Type
      • 8.1.1.3 India: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 8.1.1.3.1 Overview
        • 8.1.1.3.2 India: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 8.1.1.3.3 India: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 8.1.1.3.4 India: Vaccine Adjuvants Market Breakdown, by Type
      • 8.1.1.4 Australia: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 8.1.1.4.1 Overview
        • 8.1.1.4.2 Australia: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 8.1.1.4.3 Australia: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 8.1.1.4.4 Australia: Vaccine Adjuvants Market Breakdown, by Type
      • 8.1.1.5 South Korea: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 8.1.1.5.1 Overview
        • 8.1.1.5.2 South Korea: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 8.1.1.5.3 South Korea: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 8.1.1.5.4 South Korea: Vaccine Adjuvants Market Breakdown, by Type
      • 8.1.1.6 Rest of APAC: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 8.1.1.6.1 Overview
        • 8.1.1.6.2 Rest of APAC: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 8.1.1.6.3 Rest of APAC: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 8.1.1.6.4 Rest of APAC: Vaccine Adjuvants Market Breakdown, by Type

9. Industry Landscape

  • 9.1 Overview
  • 9.2 Growth Strategies in the Vaccine Adjuvants Market
  • 9.3 Organic Developments
    • 9.3.1 Overview
  • 9.4 Inorganic Developments
    • 9.4.1 Overview

10. Company Profiles

  • 10.1 SPI Pharma Inc
    • 10.1.1 Key Facts
    • 10.1.2 Business Description
    • 10.1.3 Products and Services
    • 10.1.4 Financial Overview
    • 10.1.5 SWOT Analysis
    • 10.1.6 Key Developments
  • 10.2 GSK Plc
    • 10.2.1 Key Facts
    • 10.2.2 Business Description
    • 10.2.3 Products and Services
    • 10.2.4 Financial Overview
    • 10.2.5 SWOT Analysis
    • 10.2.6 Key Developments
  • 10.3 CSL Ltd
    • 10.3.1 Key Facts
    • 10.3.2 Business Description
    • 10.3.3 Products and Services
    • 10.3.4 Financial Overview
    • 10.3.5 SWOT Analysis
    • 10.3.6 Key Developments
  • 10.4 Hawaii Biotech Inc
    • 10.4.1 Key Facts
    • 10.4.2 Business Description
    • 10.4.3 Products and Services
    • 10.4.4 Financial Overview
    • 10.4.5 SWOT Analysis
    • 10.4.6 Key Developments
  • 10.5 InvivoGen SAS
    • 10.5.1 Key Facts
    • 10.5.2 Business Description
    • 10.5.3 Products and Services
    • 10.5.4 Financial Overview
    • 10.5.5 SWOT Analysis
    • 10.5.6 Key Developments
  • 10.6 Croda International Plc
    • 10.6.1 Key Facts
    • 10.6.2 Business Description
    • 10.6.3 Products and Services
    • 10.6.4 Financial Overview
    • 10.6.5 SWOT Analysis
    • 10.6.6 Key Developments
  • 10.7 Novavax Inc
    • 10.7.1 Key Facts
    • 10.7.2 Business Description
    • 10.7.3 Products and Services
    • 10.7.4 Financial Overview
    • 10.7.5 SWOT Analysis
    • 10.7.6 Key Developments
  • 10.8 Phibro Animal Health Corp
    • 10.8.1 Key Facts
    • 10.8.2 Business Description
    • 10.8.3 Products and Services
    • 10.8.4 Financial Overview
    • 10.8.5 SWOT Analysis
    • 10.8.6 Key Developments

11. Appendix

  • 11.1 About The Insight Partners

List Of Tables

  • Table 1. Asia Pacific Vaccine Adjuvants Market Segmentation
  • Table 2. Asia Pacific Vaccine Adjuvants Market Revenue and Forecasts To 2030 (US$ Million)
  • Table 3. China: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 4. China: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 5. Japan: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 6. Japan: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 7. India: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 8. India: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 9. Australia: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 10. Australia: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 11. South Korea: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 12. South Korea: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 13. Rest of APAC: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 14. Rest of APAC: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 15. Organic Developments Done by Companies
  • Table 16. Inorganic Developments Done by Companies

List Of Figures

  • Figure 1. Asia Pacific Vaccine Adjuvants Market Segmentation, by Country
  • Figure 2. Impact Analysis of Drivers and Restraints
  • Figure 3. Asia Pacific Vaccine Adjuvants Market Revenue (US$ Million), 2022-2030
  • Figure 4. Asia Pacific Vaccine Adjuvants Market Share (%) - by Adjuvant Class (2022 and 2030)
  • Figure 5. Mineral Salt Adjuvant: Asia Pacific Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 6. Emulsion Adjuvant: Asia Pacific Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 7. Liposome Adjuvant: Asia Pacific Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 8. Others: Asia Pacific Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 9. Asia Pacific Vaccine Adjuvants Market Share (%) - by Type (2022 and 2030)
  • Figure 10. Human Vaccine Adjuvant: Asia Pacific Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 11. Veterinary Vaccine Adjuvant: Asia Pacific Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 12. Asia Pacific: Vaccine Adjuvants Market - Revenue by Key Countries 2022 (US$ Million)
  • Figure 13. Asia Pacific: Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%)
  • Figure 14. China: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 15. Japan: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 16. India: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 17. Australia: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 18. South Korea: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 19. Rest of APAC: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 20. Growth Strategies in the Vaccine Adjuvants Market